Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.70 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | KIT | P10721 | 7/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.46 |
| ▸ | FLT4 | P35916 | 6/20 | 0.46 |
| ▸ | FLT3 | P36888 | 6/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114985 | 1.00 | KLK7 (0.70) | KLK7KLK5OPRD1KDRKIT | |
| SCHEMBL2314134 | 0.83 | OPRD1 (0.62) | KLK7KLK5OPRD1KDRKIT | |
| SCHEMBL3366271 | 0.83 | OPRD1 (0.62) | KLK7KLK5OPRD1KDRKIT | |
| Vioxanthin SCHEMBL29800659 | 0.82 | KLK7 (1.00) | KLK7KLK5MAOAMAOBMAP3K7 | |
| SCHEMBL16226914 | 0.78 | IDO1 (0.53) | KLK7KLK5OPRD1KDRKIT | |
| SCHEMBL11036695 | 0.78 | ALDH1A1 (0.42) | KLK7KLK5KDRKITPDGFRA | |
| SCHEMBL29615880 | 0.76 | KDM4E (0.42) | KLK7KLK5OPRD1ACVRL1MAOA | |
| SCHEMBL3366320 | 0.74 | MEN1 (0.64) | KLK7KLK5OPRD1KDRKIT | |
| SCHEMBL846317 | 0.74 | KLK7 (0.73) | KLK7KLK5OPRD1KDRKIT | |
| SCHEMBL29460459 | 0.73 | KDM4E (0.45) | KLK7KLK5KDRKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | KLK7 1397/4885KLK5 1454/4885OPRD1 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.